Companies / Kuwait
If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.
Hikma - In Favour, But In Debt
January 2008 | Company News AlertSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.
In October 2007 BMI reported on Jordanian drugmaker Hikma Pharmaceuticals' bid for local rival Arab Pharmaceutical Manufacturing Company (APM). December 2007 saw the bid accepted; however, the cost to Hikma was a heavy burden of debt, as the US$163.6 deal was financed largely through borrowings. The APM move ended a busy two years for Hikma, which has seen the acquisitions of Egypt's Alkan Pharma and Germany's Riboserpharm and the purchase of the outstanding 52.5% stake in Saudi Arabian subsidiary Al Jazeera Pharmaceuticals Industries